Markolf Hanefeld E
Impact in
- Endocrinology, Diabetes and Metabolism top 0.01%
- Diabetes Treatment and Management
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Diabetes Management and Research
- Natural Antidiabetic Agents Studies
- Nephrology top 1%
- Chronic Kidney Disease and Diabetes
Papers in
-
- Diabetes Treatment and Management 136
- Diabetes, Cardiovascular Risks, and Lipoproteins 100
- Diabetes Management and Research 27
-
- Lipid metabolism and disorders 24
- Blood Pressure and Hypertension Studies 12
- Cardiovascular Health and Disease Prevention 12
- Co-authors
- Ramón Gomis (11 shared papers)Jean‐Louis Chiasson (10 shared papers)Markku Laakso (9 shared papers)Avraham Karasik (6 shared papers)Robert G. Josse (5 shared papers)Theodora S Temelkova-Kurktschiev (36 shared papers)Carsta Koehler (33 shared papers)Elena Henkel (29 shared papers)
- Journals
- Diabetes Care (26 papers)Diabetologia (16 papers)Hormone and Metabolic Research (13 papers)Atherosclerosis (11 papers)Experimental and Clinical Endocrinology & Diabetes (11 papers)
- Partner nations
- GermanyUnited KingdomUnited States
In The Last Decade
Markolf Hanefeld E
324 papers receiving 20.5k citations
Markolf Hanefeld E's Hit Papers
Peers
Comparison fields: 5 of 149
- Endocrinology, Diabetes and Metabolism 14.3k
- Nephrology 803
- Cardiology and Cardiovascular Medicine 1.8k
- Clinical Biochemistry 233
- Biochemistry 297
Countries citing papers authored by Markolf Hanefeld E
This map shows the geographic impact of Markolf Hanefeld E's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markolf Hanefeld E with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markolf Hanefeld E more than expected).
Fields of papers citing papers by Markolf Hanefeld E
This network shows the impact of papers produced by Markolf Hanefeld E. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markolf Hanefeld E. The network helps show where Markolf Hanefeld E may publish in the future.
Co-authors
The 25 scholars most cited alongside Markolf Hanefeld E, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 338 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Hit paper breakdown → | 2019 | 2345 |
| 2 | Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial Hit paper breakdown → | 2002 | 2000 |
| 3 | Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance Hit paper breakdown → | 2003 | 1356 |
| 4 | Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Hit paper breakdown → | 2009 | 1125 |
| 5 | Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up Hit paper breakdown → | 1996 | 732 |
| 6 | Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis Hit paper breakdown → | 2007 | 624 |
| 7 | 2003 | 526 | |
| 8 | 2006 | 514 | |
| 9 | Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial Hit paper breakdown → | 2019 | 498 |
| 10 | 2000 | 471 | |
| 11 | 1995 | 445 | |
| 12 | 1999 | 347 | |
| 13 | 2011 | 310 | |
| 14 | 2004 | 241 | |
| 15 | 2016 | 228 | |
| 16 | 2004 | 219 | |
| 17 | 2004 | 205 | |
| 18 | 2003 | 202 | |
| 19 | 2004 | 196 | |
| 20 | 2010 | 193 |
About Markolf Hanefeld E
Markolf Hanefeld E is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine, Surgery, Epidemiology and Physiology, having authored 338 papers that have together received 22.3k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (136 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (100 papers), Lipoproteins and Cardiovascular Health (36 papers), Diabetes Management and Research (27 papers), Adipokines, Inflammation, and Metabolic Diseases (25 papers), Lipid metabolism and disorders (24 papers), Blood Pressure and Hypertension Studies (12 papers) and Cardiovascular Health and Disease Prevention (12 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (14.3k citations), Nephrology (803 citations), Cardiology and Cardiovascular Medicine (1.8k citations), Clinical Biochemistry (233 citations) and Biochemistry (297 citations). Markolf Hanefeld E has collaborated with scholars based in Germany, United Kingdom and United States. Frequent co-authors include Ramón Gomis, Jean‐Louis Chiasson, Markku Laakso, Avraham Karasik, Robert G. Josse, Theodora S Temelkova-Kurktschiev, Carsta Koehler, Elena Henkel, Henning Beck‐Nielsen and Michel Komajda N. Their work appears in journals such as Diabetes Care, Diabetologia, Hormone and Metabolic Research, Atherosclerosis and Experimental and Clinical Endocrinology & Diabetes.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.